Cite
PO9-212 EFFECT OF ROSIGLITAZONE ON LEUKOCYTE EXPRESSION OF PROINFLAMMATORY AND PROTHROMBOTIC MOLECULES IN PATIENTS WITH TYPE 2 DIABETES
MLA
R. Dolezalova, et al. “Po9-212 Effect of Rosiglitazone on Leukocyte Expression of Proinflammatory and Prothrombotic Molecules in Patients with Type 2 Diabetes.” Atherosclerosis Supplements, vol. 8, June 2007, p. 69. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........bcfe3c19edaca5c4c22341e1561a9d74&authtype=sso&custid=ns315887.
APA
R. Dolezalova, Marinov I, Z. Kasalova, Richard Ceska, Tomáš Štulc, H. Krejci, & Helena Svitavská Svobodová. (2007). Po9-212 Effect of Rosiglitazone on Leukocyte Expression of Proinflammatory and Prothrombotic Molecules in Patients with Type 2 Diabetes. Atherosclerosis Supplements, 8, 69.
Chicago
R. Dolezalova, Marinov I, Z. Kasalova, Richard Ceska, Tomáš Štulc, H. Krejci, and Helena Svitavská Svobodová. 2007. “Po9-212 Effect of Rosiglitazone on Leukocyte Expression of Proinflammatory and Prothrombotic Molecules in Patients with Type 2 Diabetes.” Atherosclerosis Supplements 8 (June): 69. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........bcfe3c19edaca5c4c22341e1561a9d74&authtype=sso&custid=ns315887.